Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
Abstract Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of prostaglandin E2 and release of leukotrienes....
Main Authors: | Tiago Azenha Rama, José Mário Morgado, Ana Henriques, Luis Escribano, Iván Alvarez‐Twose, Laura Sanchez‐Muñoz, André Moreira, José Romão, Alberto Órfão, Almudena Matito |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-03-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | https://doi.org/10.1002/clt2.12132 |
Similar Items
-
A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders
by: Jan Romantowski, et al.
Published: (2021-02-01) -
Insights in Anaphylaxis and Clonal Mast Cell Disorders
by: David González-de-Olano, et al.
Published: (2017-07-01) -
Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis
by: Knut Brockow, et al.
Published: (2021-03-01) -
Editorial: The Role of Mast Cells in Immediate Hypersensitivity Reactions
by: Marcelo Vivolo Aun, et al.
Published: (2021-10-01) -
Type II mast cells in mast cell leukemia: Uncommon yet clinically significant
by: Constance P. Chen, et al.
Published: (2024-04-01)